RTW Investments, LP
About RTW Investments, LP’s 13F portfolio
RTW Investments, LP is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , RTW Investments, LP reported $11.7B across 84 US-listed positions (). Its largest position is MADRIGAL PHARMACEUTICALS INC (MDGL) at 9.1% of the reported book, and its ten biggest holdings make up 48% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: MDGL MADRIGAL PHARMACEUTICALS INC | — — | 9.1% | 2.0M | $1.1B |
| 2 | NASDAQ: ARGX ARGENX SE | — — | 5.6% | 709K | $658.2M |
| 3 | NASDAQ: PTCT PTC THERAPEUTICS INC | — — | 5.4% | 7.7M | $631.9M |
| 4 | NASDAQ: PTGX PROTAGONIST THERAPEUTICS INC | — — | 5.3% | 5.1M | $620.4M |
| 5 | NASDAQ: CGON CG ONCOLOGY INC | — — | 5.2% | 8.5M | $605.0M |
| 6 | NASDAQ: INSM INSMED INC | — — | 4.4% | 4.8M | $516.3M |
| 7 | NASDAQ: TNGX TANGO THERAPEUTICS INC | — — | 3.7% | 13.9M | $434.5M |
| 8 | NASDAQ: SYRE SPYRE THERAPEUTICS INC | — — | 3.2% | 4.3M | $377.5M |
| 9 | NASDAQ: CELC CELCUITY INC | — — | 3.0% | 3.3M | $345.8M |
| 10 | NASDAQ: ERAS ERASCA INC | — — | 2.8% | 17.9M | $328.8M |
| 11 | NASDAQ: RDNT RADNET INC | — — | 2.6% | 4.8M | $298.9M |
| 12 | NASDAQ: ORKA ORUKA THERAPEUTICS INC | — — | 2.6% | 3.1M | $298.7M |
| 13 | NASDAQ: NTRA NATERA INC | — — | 2.3% | 1.0M | $271.4M |
| 14 | NASDAQ: RARE ULTRAGENYX PHARMACEUTICAL IN | — — | 2.2% | 7.8M | $260.3M |
| 15 | NASDAQ: IRTC IRHYTHM HOLDINGS INC | — — | 2.2% | 2.2M | $259.6M |
| 16 | NASDAQ: CYTK CYTOKINETICS INC | — — | 2.1% | 2.9M | $243.8M |
| 17 | NASDAQ: KLRA KAILERA THERAPEUTICS INC | — — | 2.0% | 10.8M | $237.4M |
| 18 | NASDAQ: ESTA ESTABLISHMENT LABS HLDGS INC | — — | 1.9% | 2.7M | $227.9M |
| 19 | NASDAQ: GH GUARDANT HEALTH INC | — — | 1.9% | 1.5M | $222.2M |
| 20 | NASDAQ: NBIX NEUROCRINE BIOSCIENCES INC | — — | 1.8% | 1.3M | $213.7M |
| 21 | NASDAQ: TARS TARSUS PHARMACEUTICALS INC | — — | 1.8% | 3.4M | $211.3M |
| 22 | NASDAQ: STOK STOKE THERAPEUTICS INC | — — | 1.6% | 5.6M | $184.0M |
| 23 | NASDAQ: QURE UNIQURE NV | — — | 1.5% | 3.9M | $181.5M |
| 24 | NASDAQ: ACAD ACADIA PHARMACEUTICALS INC | — — | 1.5% | 7.1M | $180.8M |
| 25 | NASDAQ: RGEN REPLIGEN CORP | — — | 1.4% | 1.2M | $169.3M |
Showing 1–25 of 84 positions on this page reported in this 13F.
- Healthcare97%
- Financial Services0.1%
- AddedPTGXPROTAGONIST THERAPEUTICS INC+0.0%$620.4M
- AddedCGONCG ONCOLOGY INC+21.9%$605.0M
- AddedTNGXTANGO THERAPEUTICS INC+4.5%$434.5M
- AddedSYRESPYRE THERAPEUTICS INC+1.9%$377.5M
- AddedCELCCELCUITY INC+8.7%$345.8M
- AddedERASERASCA INC+11.1%$328.8M
- AddedRDNTRADNET INC+13.1%$298.9M
- AddedORKAORUKA THERAPEUTICS INC+52.5%$298.7M
- AddedRAREULTRAGENYX PHARMACEUTICAL IN+114%$260.3M
- AddedIRTCIRHYTHM HOLDINGS INC+30.8%$259.6M
- ReducedNTRANATERA INC−20.0%$271.4M
- ReducedTSHATAYSHA GENE THERAPIES INC−0.9%$92.3M
- ReducedCOGTCOGENT BIOSCIENCES INC−57.7%$89.4M
- ReducedHNGEHINGE HEALTH INC−74.1%$41.5M
- ReducedBBNXBETA BIONICS INC−25.0%$23.5M
- ReducedHTFLHEARTFLOW INC−40.4%$8.7M
- ReducedAVTXAVALO THERAPEUTICS INC−79.6%$3.2M
- ReducedXGNEXAGEN INC−50.7%$907K
- SoldAPLSAPELLIS PHARMACEUTICALS INC−100%—
- SoldISRGINTUITIVE SURGICAL INC−100%—
Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.
| # | Stock | Type | % of class | Shares | Filed |
|---|---|---|---|---|---|
| 1 | OBIO ORCHESTRA BIOMED HOLDINGS, INC. | 13D | 19.7% · 2 classes | 11.9M | Filed 25 FEB 2026 |
| 2 | STOK Stoke Therapeutics, Inc. | 13G | 10.0% · 2 classes | 5.3M | Filed 14 FEB 2025 |
| 3 | ESTA Establishment Labs Holdings Inc. | 13G | 10.0% | 2.8M | Filed 14 FEB 2025 |
| 4 | CMPS COMPASS Pathways plc | 13G | 9.9% · 2 classes | 9.5M | Filed 14 AUG 2025 |
| 5 | VSTM Verastem, Inc. | 13G | 9.9% · 2 classes | 9.0M | Filed 15 MAY 2026 |
| 6 | PYXS Pyxis Oncology, Inc. | 13G | 9.9% | 8.5M | Filed 16 NOV 2026 |
| 7 | TENX Tenax Therapeutics, Inc. | 13G | 9.9% | 651K | Filed 17 FEB 2026 |
| 8 | ALUR ALLURION TECHNOLOGIES, INC. | 13D | 9.9% · 2 classes | 67K | Filed 02 SEP 2026 |
| 9 | CGON CG Oncology, Inc. | 13G | 9.7% | 8.5M | Filed 14 AUG 2026 |
| 10 | IMTX Immatics N.V. | 13G | 9.6% · 2 classes | 12.9M | Filed 15 MAY 2026 |
| 11 | TNGX Tango Therapeutics, Inc. | 13G | 9.3% | 13.3M | Filed 15 MAY 2026 |
| 12 | ZLAB Zai Lab Limited | 13G | 9.2% · 2 classes | 103.5M | Filed 16 NOV 2026 |
| 13 | REPL Replimune Group, Inc. | 13G | 9.0% · 2 classes | 8.5M | Filed 16 NOV 2026 |
| 14 | GHRS GH Research PLC | 13G | 8.9% | 5.5M | Filed 15 MAY 2025 |
| 15 | TSHA TAYSHA GENE THERAPIES, INC. | 13G | 8.3% · 2 classes | 23.4M | Filed 17 FEB 2026 |
| 16 | KLRA Kailera Therapeutics, Inc. | 13G | 8.3% | 10.8M | Filed 14 AUG 2026 |
| 17 | TARS Tarsus Pharmaceuticals, Inc. | 13G | 8.1% | 3.4M | Filed 14 AUG 2025 |
| 18 | RARE Ultragenyx Pharmaceutical Inc. | 13G | 7.9% | 7.8M | Filed 14 AUG 2026 |
| 19 | IPSC Century Therapeutics, Inc. | 13G | 7.1% | 13.0M | Filed 15 MAY 2026 |
| 20 | ERAS Erasca, Inc. | 13G | 6.4% | 22.4M | Filed 16 NOV 2026 |
| 21 | CELC Celcuity Inc. | 13G | 6.3% | 3.0M | Filed 15 MAY 2026 |
| 22 | RDNT RadNet, Inc. | 13G | 6.2% · 2 classes | 4.8M | Filed 14 AUG 2026 |
| 23 | SYRE Spyre Therapeutics, Inc. | 13G | 6.2% | 3.6M | Filed 14 FEB 2025 |
| 24 | QURE uniQure N.V. | 13G | 6.0% · 2 classes | 3.7M | Filed 17 FEB 2026 |
| 25 | — RAPT THERAPEUTICS, INC. | 13G | 5.9% | 1.6M | Filed 17 FEB 2026 |
Showing 1–25 of 28 disclosed stakes. 6 last disclosed over a year ago (the holder may since have dropped below 5%).
Reading RTW Investments, LP’s 13F portfolio
RTW Investments, LP’s $11.7B 13F book is spread across 84 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 48%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are MDGL, ARGX, PTCT, PTGX and CGON, led by MADRIGAL PHARMACEUTICALS INC (MDGL) at 9.1% of the portfolio. The heaviest sector exposure is Healthcare (97%), then Financial Services (0%).
What RTW Investments, LP changed last quarter
Between 2026-03-31 and Q2 2026, RTW Investments, LP was a net buyer: it opened 9 new positions and added to 26 more, while trimming 8 and closing 13 outright. Against a 84-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was PROTAGONIST THERAPEUTICS INC (PTGX), and its biggest reduction was NATERA INC (NTRA).
What a 13F does and doesn’t reveal
A 13F captures only RTW Investments, LP’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names RTW Investments, LP is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. RTW Investments, LP's profile on this page is built directly from those filings.
How current is the 13F data on RTW Investments, LP's page?
It reflects RTW Investments, LP's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When RTW Investments, LP files its next quarterly report, this page refreshes automatically.
Can I see RTW Investments, LP's complete list of holdings?
This page highlights RTW Investments, LP's largest positions rather than all 84 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under RTW Investments, LP's filings.
Does a 13F show everything RTW Investments, LP owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of RTW Investments, LP's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why RTW Investments, LP made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

